학술논문
Randomized phase III study comparing the efficacy and safety of CT-P16, a new biosimilar, to reference bevacizumab (Avastin (R)) in patients with metastatic or recurrent non-small cell lung cancer (NSCLC)
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15387445